BECTON, DICKINSON AND COMPANY

(BDX)
  Report
Delayed Nyse  -  04:00 2022-08-12 pm EDT
263.69 USD   +1.65%
08/12INSIDER SELL : Becton Dickinson & Co.
MT
08/12INSIDER SELL : Becton Dickinson & Co.
MT
08/09BECTON DICKINSON & CO : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Becton, Dickinson and Company Recalls Intraosseous Products

06/23/2022 | 03:29am EDT


© MT Newswires 2022
All news about BECTON, DICKINSON AND COMPANY
08/12INSIDER SELL : Becton Dickinson & Co.
MT
08/12INSIDER SELL : Becton Dickinson & Co.
MT
08/09BECTON DICKINSON & CO : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
08/09Becton, Dickinson and Company, Labcorp Collaborate to Develop Flow Cytometry-Based Comp..
CI
08/08BECTON DICKINSON AND : Announces Tender Offers for Outstanding Debt Securities - Form 8-K
PU
08/08BECTON DICKINSON & CO : Other Events (form 8-K)
AQ
08/08BD Announces Tender Offers for Outstanding Debt Securities
PR
08/08BECTON, DICKINSON AND COMPANY : SEC Filing 8K
CO
08/04BECTON DICKINSON & CO Management's Discussion and Analysis of Financial Condition and ..
AQ
08/04SECTOR UPDATE : Health Care Stocks Mixed Pre-Bell Thursday
MT
More news
Analyst Recommendations on BECTON, DICKINSON AND COMPANY
More recommendations
Financials (USD)
Sales 2022 18 845 M - -
Net income 2022 1 866 M - -
Net Debt 2022 13 567 M - -
P/E ratio 2022 38,6x
Yield 2022 1,44%
Capitalization 75 203 M 75 203 M -
EV / Sales 2022 4,71x
EV / Sales 2023 4,50x
Nbr of Employees 75 000
Free-Float 77,6%
Chart BECTON, DICKINSON AND COMPANY
Duration : Period :
Becton, Dickinson and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BECTON, DICKINSON AND COMPANY
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Last Close Price 263,69 $
Average target price 274,67 $
Spread / Average Target 4,16%
EPS Revisions
Managers and Directors
Thomas E. Polen Chairman, President & Chief Executive Officer
Christopher J. DelOrefice Chief Financial Officer & Executive Vice President
William R. Sigmund Chief Medical Officer & Executive Vice President
Elizabeth McCombs Senior Vice President-Research & Development
Joseph M. Smith Chief Scientific Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
BECTON, DICKINSON AND COMPANY7.29%75 203
ABBOTT LABORATORIES-20.79%195 226
MEDTRONIC PLC-8.34%125 988
HOYA CORPORATION-14.17%39 624
SARTORIUS STEDIM BIOTECH-20.96%36 037
DEXCOM, INC.-33.08%35 266